ClinicalTrials.gg
Enrolling by invitationNCT04141605GUARDIANUpdated Oct 16, 2026

Global Utilization And Registry Database for Improved heArt preservatioN

An observational study in Heart Diseases, Heart Failure and Heart Defects, Congenital, sponsored by Paragonix Technologies. Enrolling by invitation at 22 sites in 4 countries. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Paragonix Technologies · Observational

How we know

Updated Oct 16, 2026Primary completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
4,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 646 studies in Heart Diseases with a site in United States — 92 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.

Planned enrollment
30th of 206
4,000 · median 300
Started
2020
with 28 others
Observational
211 of 646
32 open now
Primary completion
2028-12
later than 91 of 128 live
Registered
476th of 646
by date

Among the 646 studies in Heart Diseases with a site in United States, this one is the 30th largest by planned enrollment of the 206 observational ones that give a count, is one of 29 that started in 2020, is one of 211 observational ones, reaches primary completion later than 91 of the 128 other live ones, and was the 476th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

92 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 646 studies in Heart Diseases with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

CONCERT DCD is a substudy designed to assess the safety and feasibility of a direct procurement method for donation after circulatory death (DCD) heart procurement (CONCERT DCD) that utilizes preservation in a SherpaPak Cardiac Transport System. This DCD Substudy will be limited to approved GUARDIAN-Heart Registry sites who have been qualified to participate. The DCD Substudy will include prospective recipient identification and documentation of informed consent.

Read the detailed description

This study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. The study is a chart review study.

Ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution.

This study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. Subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1-year, 2-years, 3-years, 4-years, 5-years).

GUARDIAN provides critical and contemporary data on patient outcomes, with additional insight into risk factors and patient-related indices. Both donor and recipient information along with procedural details (including transportation) will be collected to provide information for major discrete endpoints such as death, primary graft dysfunction, right ventricular dysfunction, CPB weaning, Inotrope use, CAV diagnosis, rejection, and survival.

Information about re-hospitalizations and re-transplantations is vital to address the integrated endpoint of days alive out of hospital, which is particularly relevant for this patient population. In addition, the number of in-hospital days and ICU time is closely tracked as the major resource utilized, after the initial transplant.

CONCERT DCD Substudy:

CONCERT DCD, Cold Oxygenated Flush, No reanimation, Controlled Preservation Technique for DCD , is a cold oxygenated non-reanimation perfusion method using blood, bicarbonate and Wisconsin (UW) Preservation Solution. Hearts are procured following a cold, buffered blood flush (150 mL/min for approximately 20 minutes), followed by arrest with standard UW preservative. This utilizes a simplified perfusion circuit consisting of a centrifugal pump, reservoir, oxygenator, and heater/cooler. The same datapoints will be collected for this study. In addition to the Donor and Recipient inclusion criteria in the overall GUARDIAN heart registry, the following additional criteria will be required in the CONCERT DCD Substudy:

Recipient: Status 1 or 2

Recipients with Congenital heart etiologies will be excluded.

Donors: Aged 16-40

Anticipated total ischemic time (cross clamp time) \<5 hours

Echo-confirmed functionally normal heart

No prior coronary disease, including significant valvular or ventricular dysfunction

03

Conditions studied

  • Heart Diseases
  • Heart Failure
  • Heart Defects, Congenital
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients registered on the heart transplant registry who receive a heart transplant at a participating center and do not meet any of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Donor and donor hearts matched to the prospective recipient based upon institutional medical practice
  • Registered male or female primary heart transplant candidates including pediatric candidates

Exclusion criteria

Exclusion Criteria:

  • Donor and donor hearts that do not meet institutional clinical requirements for transplantation
  • When safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root
  • Patients who are incarcerated persons (prisoners)
  • Patients who have had a previous organ transplant
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
4,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • SherpaPak CTS Patients

    Patients whose donor heart was transported with the SherpaPak CTS

    Device: SherpaPak Cardiac Transport System

  • Standard Transport Patients

    Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years

  • CONCERT DCD

    Patients whose DCD heart was procured using a cold oxygenated flush with no reanimation and then transported in the SherpaPak CTS

Interventions

  • DeviceSherpaPak Cardiac Transport System

    The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.

    Also known as: SherpaPak CTS

06

What researchers measure

Primary outcomes

  1. Number of Patients with Primary Graft Dysfunction

    Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m\^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour)

    Time frame: one year

  2. Number of Patients with Right Ventricular Dysfunction

    hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m\^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD

    Time frame: one year

  3. Length of ICU Stay

    Length of time patient admitted to the intensive care unit post transplant

    Time frame: one year

  4. Length of Hospital Stay

    Length of time before patient is discharged from the hospital post transplant

    Time frame: one year

  5. Survival

    The length of patient survival up to 5 years will be compared

    Time frame: 5 years

Secondary outcomes

  1. Hospitalizations

    Number of related hospitalizations post transplant

    Time frame: one year

  2. CAV development

    Number of patients who developed CAV between 1 and 5 years post transplant will be compared

    Time frame: five years

  3. Retransplant

    The number of patients who were retransplanted will be compared

    Time frame: five years

07

Study locations

22 sites
08

References and documents

Publications

  • DeFilippis EM, Rodrigo ME, Loyaga-Rendon R, Shudo Y, Uriel N, Takeda K, D'Alessandro DA, Fiedler A. Preservation Strategy and Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis. ASAIO J. 2026 May 13. doi: 10.1097/MAT.0000000000002736. Online ahead of print. PubMed 42127213 ↗
  • Lerman JB, Patel CB, Casalinova S, Nicoara A, Holley CL, Leacche M, Silvestry S, Zuckermann A, D'Alessandro DA, Milano CA, Schroder JN, DeVore AD. Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System. Circ Heart Fail. 2024 May;17(5):e010904. doi: 10.1161/CIRCHEARTFAILURE.123.010904. Epub 2024 Apr 11. PubMed 38602105 ↗
  • D'Alessandro D, Schroder J, Meyer DM, Vidic A, Shudo Y, Silvestry S, Leacche M, Sciortino CM, Rodrigo ME, Pham SM, Copeland H, Jacobs JP, Kawabori M, Takeda K, Zuckermann A. Impact of controlled hypothermic preservation on outcomes following heart transplantation. J Heart Lung Transplant. 2024 Jul;43(7):1153-1161. doi: 10.1016/j.healun.2024.03.010. Epub 2024 Mar 19. PubMed 38503386 ↗
  • Moayedifar R, Shudo Y, Kawabori M, Silvestry S, Schroder J, Meyer DM, Jacobs JP, D'Alessandro D, Zuckermann A. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry. J Heart Lung Transplant. 2024 Apr;43(4):673-680. doi: 10.1016/j.healun.2023.12.013. Epub 2023 Dec 30. PubMed 38163452 ↗
  • Shudo Y, Leacche M, Copeland H, Silvestry S, Pham SM, Molina E, Schroder JN, Sciortino CM, Jacobs JP, Kawabori M, Meyer DM, Zuckermann A, D'Alessandro DA. A Paradigm Shift in Heart Preservation: Improved Post-transplant Outcomes in Recipients of Donor Hearts Preserved With the SherpaPak System. ASAIO J. 2023 Nov 1;69(11):993-1000. doi: 10.1097/MAT.0000000000002036. Epub 2023 Apr 5. PubMed 37678260 ↗

Individual participant data

Plan to share: No — Data will only be released as a summary of the results found at each center and overall. No individual patient data will be released.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2020 (actual). Primary completion is estimated for Dec 2028, 106 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Oct 28, 2019
StartActual
Feb 14, 2020
Primary completionEst.
Dec 31, 2028was Dec 2027
CompletionEst.
Dec 31, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Medstar Washington Hospital · Washington D.C., United States
Show 1 removed
  • Medstar Washington Hospital · Washington DC, United States
Oct 16, 2026
Primary completion
Dec 31, 2027→Dec 31, 2028
Oct 16, 2026
Enrollment
3000→4000
Oct 16, 2026
Interventions
Arms added: CONCERT DCD
Oct 16, 2026
Publications
5 publications citing this study linked from PubMed, e.g. PubMed 42127213 ↗
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Publications 5 publications citing this study linked from PubMed, e.g. PubMed 42127213 ↗
    1 site added, 1 site removed
    Show site
    • Medstar Washington Hospital · Washington D.C., United States
    Show 1 removed
    • Medstar Washington Hospital · Washington DC, United States
    Primary completion Dec 31, 2027→Dec 31, 2028
    Enrollment 3000→4000
    Interventions Arms added: CONCERT DCD
    + 4 other changes: index terms, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04141605
Lead sponsor
Paragonix Technologies
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Feb 14, 2020
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Andreas Zuckermann, MD
principal investigator · ALLGEMEINES KRANKENHAUS WIEN

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion